Every Form 4 that Sana Biotechnology, Inc. (SANA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SANA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SANA filings page.
Sana Biotechnology, Inc. director Hans Edgar Bishop acquired 8,680 shares of common stock on October 5, 2026. The award consisted of fully vested restricted stock units. His reported direct common-stock holdings following the transaction were 5,863,480 shares.
Sana Biotechnology, Inc. (SANA) reported insider equity transactions by EVP and Chief Scientific Officer Dhavalkumar Dhirajlal Patel. On August 26, 2026, he exercised 125,000 Restricted Stock Units, receiving 125,000 shares of common stock, and his RSU position was reported as 250,000 units afterward. On August 27, 2026, 41,158 common shares were delivered or withheld at $4.11 per share for payment of exercise price or tax liability related to the equity award.
Sana Biotechnology director Hans Edgar Bishop reported an equity award. He received 6,297 shares of Common Stock as a grant with a price per share of $0.00, consisting of fully vested restricted stock units. After this compensation-related acquisition, his directly held stake increased to 5,854,800 shares.
Sana Biotechnology director Patrick Y. Yang received a new stock option grant, giving him the right to acquire 90,000 shares of common stock at an exercise price of $2.96 per share. The option vests in full on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting, as long as he continues providing service to the company. Following this award, he holds 90,000 derivative securities linked to Sana common stock directly.
Sana Biotechnology director Robert L. Rosiello received a grant of stock options covering 90,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest in full on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting, assuming he remains in continuous service.
Sana Biotechnology director Michelle Seitz received a grant of stock options for 90,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest and become fully exercisable on the earlier of June 4, 2027 or immediately prior to Sana’s 2027 annual stockholder meeting, as long as she continues to provide service to the company through that date. Following this award, she holds 90,000 stock options directly, reflecting a compensation-related acquisition rather than an open-market share purchase.
Sana Biotechnology director Alise Reicin received a grant of stock options covering 90,000 shares of common stock. The options have an exercise price of $2.96 per share and will expire on June 3, 2036.
The option vests in full as to all 90,000 underlying shares on the earlier of June 4, 2027 or immediately before Sana Biotechnology’s 2027 annual meeting of stockholders, as long as Reicin continues providing service to the company through that date. Following this grant, she holds options on 90,000 shares directly.
Sana Biotechnology director Richard Mulligan received a grant of stock options covering 90,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest 100% on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholders’ meeting, if he continues serving the company. Following this grant, he holds 90,000 options directly.
Sana Biotechnology, Inc. director Hans Edgar Bishop received a grant of stock options covering 90,000 shares of Common Stock at an exercise price of $2.96 per share. Following this grant, he holds options on 90,000 shares directly.
The options vest and become exercisable for all 90,000 underlying shares on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual meeting of stockholders, provided he continues to serve the company through that date.
Sana Biotechnology, Inc. director Joshua H. Bilenker received a grant of stock options covering 90,000 shares of common stock. The options have an exercise price of $2.9600 per share and expire on June 3, 2036.
These options vest and become exercisable in full on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual meeting of stockholders, provided he continues to serve the company through that date. Following this grant, he holds 90,000 derivative securities directly.
Sana Biotechnology director Robert Nelsen received a grant of stock options covering 90,000 shares of Common Stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest 100% on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting, assuming continuous service. Following this grant, Nelsen holds options for 90,000 shares directly.
Bishop Hans Edgar reported acquisition or exercise transactions in this Form 4 filing.
Sana Biotechnology, Inc. director Hans Edgar Bishop received an award of 7,763 shares of Common Stock on April 6, 2026. The filing notes these shares consist of fully vested restricted stock units granted at no cash cost per share, as part of his equity compensation.
After this grant, Bishop directly holds a total of 5,848,503 shares of Common Stock. Because the shares were awarded rather than bought in the open market, this transaction is primarily a routine compensation event, not a market purchase or sale.
Sana Biotechnology President & CEO Steve Harr reported routine equity compensation activity. On March 6 and 7, 2026, he exercised restricted stock units to acquire a total of 91,666 shares of common stock at $0.00 per share. Related to these vestings, on March 9, 2026, 11,526 shares and 12,819 shares of common stock were disposed of at approximately $3.13 and $3.10 per share, respectively, to satisfy tax liabilities. Following these transactions, Harr directly holds 7,944,251 shares of Sana common stock, with additional indirect holdings reported through family trusts. Footnotes explain that the RSU awards vest over several years, contingent on Harr’s continued service with Sana.
Sana Biotechnology, Inc. officer Susan D. Wyrick exercised restricted stock units into common stock and had shares withheld to cover taxes. On March 6–7, she converted a total of 13,666 restricted stock units into the same number of common shares at a stated price of $0.00. On March 9, 4,387 common shares were disposed of at about $3.11 per share as tax-withholding transactions, not open-market sales. After these moves, she directly held 196,196 common shares, with additional restricted stock units scheduled to vest over several years, subject to continued service.
Sana Biotechnology, Inc. reported that officer Susan D. Wyrick acquired new equity awards. She received 45,833 restricted stock units and a stock option for 206,250 shares on March 5, 2026, both at a grant price of $0.00 per unit or option.
The restricted stock units vest in four equal installments on March 5 of 2027, 2028, 2029 and 2030, conditioned on continued service with Sana. The stock option vests as to 25% of the underlying shares on March 5, 2027 and then in 36 equal monthly installments, also requiring continuous service.
Sana Biotechnology President & CEO Steve Harr received new equity awards. On March 5, he was granted 200,000 restricted stock units and stock options for 900,000 shares of Sana common stock, both at a per-share exercise price of $0.00.
The 200,000 restricted stock units each represent a right to receive one share of Sana common stock and vest in four equal installments on March 5 of 2027, 2028, 2029 and 2030, if he continues to serve the company. The 900,000-share stock option vests as to 25% of the underlying shares on March 5, 2027, then in 36 equal monthly installments thereafter, also conditioned on continued service.
Sana Biotechnology, Inc. officer Susan D. Wyrick reported equity transactions involving restricted stock units and common shares. On March 2, 2026, 1,525 restricted stock units were exercised into 1,525 shares of common stock at $0.00 per share, increasing her direct holdings to 187,408 common shares. On March 3, 2026, 491 common shares were disposed of at $3.91 per share to satisfy tax withholding obligations, leaving 186,917 common shares directly owned. Each restricted stock unit represents a right to receive one share of Sana common stock, vesting in four annual 25% installments on March 2 of 2024, 2025, 2026 and 2027, subject to continued service.
Piper Brian reported acquisition or exercise transactions in this Form 4 filing.
Sana Biotechnology, Inc. reported that EVP and Chief Financial Officer Brian Piper received new equity awards. He was granted 200,000 restricted stock units, each representing a right to receive one share of common stock, and a stock option for 900,000 shares.
The restricted stock units vest in four equal installments on February 17 of 2027, 2028, 2029 and 2030, if he continues providing service through each date. The stock option vests as to 25% of the shares on February 17, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, also subject to continued service.
Sana Biotechnology director Hans Edgar Bishop reported an equity award. On January 5, 2026, he acquired 6,157 shares of Common Stock in a transaction coded "A" for acquisition. The footnote explains these consist of fully vested restricted stock units, with a reported price of $0.00 per share, indicating no cash purchase. After this grant, Bishop is shown as beneficially owning 5,840,740 shares of Sana Biotechnology common stock in direct ownership.
Sana Biotechnology, Inc. officer Susan D. Wyrick, identified as Acting Chief Financial Officer and Principal Accounting Officer, reported equity transactions involving company stock. On January 2, 2026, 7,500 restricted stock units were converted to common stock at $0.00 per share, reflecting previously granted compensation that vested 40% on January 2, 2025 and 60% on January 2, 2026. The corresponding RSU award balance went to zero after this conversion.
On January 5, 2026, Wyrick reported a transaction coded "F" involving 2,407 shares of common stock at $4.27 per share, after which she directly held 185,883 shares of Sana Biotechnology common stock.
Sana Biotechnology, Inc. officer Susan D. Wyrick reported activity in company stock. On December 13, 2025, 3,400 restricted stock units vested and converted into common stock at a price of $0.00 per share, increasing her directly held shares. On December 15, 2025, she disposed of 873 shares at $5.22 per share, after which she held 180,790 shares of common stock directly. The filing notes that the restricted stock unit award vested in full on December 13, 2025 and identifies Wyrick as Acting Chief Financial Officer and Principal Accounting Officer.